BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer
Shots:
- The P-III CheckMate -227 Part 1a study involves assessing of Opdivo + Yervoy vs platinum-doublet CT in patients with 1L advanced NSCLC across non-squamous and squamous tumor expressing PD-L1 ≥1%
- The P-III Checkmate -227 Part 1a study resulted in meeting its 1EPs of overall survival. BMS also announced that Part 2 of CheckMate -227 study evaluating Opdivo plus CT- did not meet its 1EPs of OS in patients with 1L non-sq NSCLC regardless of PD-L1 status
- Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system to restore anti-tumor immune response- indicated as monothx. or in combination with Yervoy to treat multiple cancer
Click here- Click here to read full press release/ article |
Ref: BMS | Image: BMS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com